Related Experiment Video
Updated: Apr 11, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Effect of comorbidity on mortality in multiple sclerosis
Ruth Ann Marrie1, Lawrence Elliott2, James Marriott2
1From the Departments of Internal Medicine (R.A.M., J.M., M.C.) and Community Health Sciences (R.A.M., L.E., J.B., S.L., N.Y.), University of Manitoba, Winnipeg; Epidemiology and Surveillance (N.Y.), Public Health and Primary Care Division, Manitoba Health, Winnipeg, Canada. rmarrie@hsc.mb.ca.
Objective:
We aimed to compare survival in the multiple sclerosis (MS) population with a matched cohort from the general population, and to evaluate the association of comorbidity with survival in both populations.
Methods:
Using population-based administrative data, we identified 5,797 persons with MS and 28,807 controls matched on sex, year of birth, and region. We estimated annual mortality rates. Using Cox proportional hazards regression, we evaluated the association between comorbidity status and mortality, stratifying by birth cohort, and adjusting for sex, socioeconomic status, and region. We compared causes of death between populations.
Results:
Median survival from birth in the MS population was 75.9 years vs 83.4 years in the matched population. MS was associated with a 2-fold increased risk of death (adjusted hazard ratio 2.40; 95% confidence interval: 2.24-2.58). Several comorbidities were associated with increased hazard of death in both populations, including diabetes, ischemic heart disease, depression, anxiety, and chronic lung disease. The magnitude of the associations of mortality with chronic lung disease, diabetes, hypertension, and ischemic heart disease was lower in the MS population than the matched population. The most common causes of death in the MS population were diseases of the nervous system and diseases of the circulatory system. Mortality rates due to infectious diseases and diseases of the respiratory system were higher in the MS population.
Conclusion:
In the MS population, survival remained shorter than expected. Within the MS population, comorbidity was associated with increased mortality risk. However, comorbidity did not preferentially increase mortality risk in the MS population as compared with controls.
More Related Videos
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Comparing the Survival Analysis of Two or More Groups
Heart Failure III: Clinical Manifestations
Pharmacodynamics in Geriatric Patients: Effects of Age
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...